ASLAN Receives Second US Orphan Drug Designation for Cancer Drug

ASLAN Pharma, a Singapore biotech company developing immunotherapies and targeted drugs for cancers that are prevalent in Asia, was granted US Orphan drug designation for varlitinib (ASLAN001) in gastric cancer. It was the second US Orphan drug for varlitinib, a pan-HER inhibitor. One year ago, varlitinib was given US FDA Orphan drug status for cholangiocarcinoma). ASLAN in-licensed rights to the drug candidate in 2011 from Array BioPharma. More details.... Stock Symbol: (NSDQ: ASLN) Share this with colleagues: // //